$PYPD Polipid - Big partnership just dropped + NDA momentum. Short-term setup looking interesting.

PolyPid ($PYPD) just locked in a major exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX₁₀₀ in the U.S. and Canada (prevention of surgical site infections).

Key terms:

* $15M upfront at signing
* Another $15M upon expected FDA acceptance of the NDA (targeted for August 2026)
* Up to \~$300M more in regulatory, development, and sales milestones
* Tiered royalties mid-teens to mid-twenties %
* PolyPid keeps manufacturing rights worldwide + all rights outside U.S./Canada + full ownership of the PLEX platform

This comes right after they completed the NDA submission in June. PDUFA target is currently Q1 2027, with U.S. launch eyed for around then. Earlier Phase 3 SHIELD II data showed the primary endpoint hit plus a 60% relative risk reduction on a key secondary.

Market cap is still only \~$75-85M range (depending on the day), with \~19M shares outstanding and float roughly in the 7-11M area. Analyst targets have been sitting around $11-13.

Near-term catalysts:

* FDA acceptance of the NDA (the next $15M payment)
* Any updates on the partnership rollout or additional label-expansion talk
* Continued institutional interest / visibility

The Azurity deal de-risks commercialization significantly and puts real cash + future royalties on the table while they retain the platform upside. Still under the radar relative to the potential scale of the SSI prevention market.

Not financial advice. Do your own research, size positions carefully, and remember biotech can be extremely volatile. Just laying out the recent milestones and the short-term setup as I see it.

What are your thoughts on $PYPD here?